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Background: Dengue virus (DENV) research has historically been hampered by the lack of a susceptible vertebrate
transmission model. Recently, there has been progress towards such models using several varieties of knockout
mice, particularly those deficient in type I and II interferon receptors. Based on the critical nature of the type I
interferon response in limiting DENV infection establishment, we assessed the permissiveness of a mouse strain
with a blunted type I interferon response via gene deficiencies in interferon regulatory factors 3 and 7 (IRF3/7 −/− −/−)
with regards to DENV transmission success. We investigated the possibility of transmission to the mouse by needle
and infectious mosquito, and subsequent transmission back to mosquito from an infected animal during its
viremic period.
Methods: Mice were inoculated subcutaneously with non-mouse adapted DENV-2 strain 1232 and serum was
tested for viral load and cytokine production each day. Additionally, mosquitoes were orally challenged with the
same DENV-2 strain via artificial membrane feeder, and then allowed to forage or naïve mice. Subsequently, we
determined acquisition potential by allowing naïve mosquitoes on forage on exposed mice during their viremic
period.
Results: Both needle inoculation and infectious mosquito bite(s) resulted in 100% infection. Significant differences
between these groups in viremia on the two days leading to peak viremia were observed, though no significant
difference in cytokine production was seen. Through our determination of transmission and acquisition potentials,
the transmission cycle (mouse-to mosquito-to mouse) was completed. We confirmed that the IRF3/7 −/− −/−
mouse supports DENV replication and is competent for transmission experiments, with the ability to use a non-
mouse adapted DENV-2 strain. A significant finding of this study was that this IRF3/7 −/− −/− mouse strain was able
to be infected by and transmit virus to mosquitoes, thus providing means to replicate the natural transmission
cycle of DENV.
Conclusion: As there is currently no approved vaccine for DENV, public health monitoring and a greater
understanding of transmission dynamics leading to outbreak events are critical. The further characterization of
DENV using this model will expand knowledge of key entomological, virological and immunological components
of infection establishment and transmission events.
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Dengue virus (DENV) is the most common arboviral in-
fection of humans, infecting tens of millions of people
each year in tropical areas [1]. There is presently no vac-
cine available for DENV and reducing transmission via
mosquito control efforts has not yet been sufficient to
alter the trajectory of the pandemic [2]. DENV is effi-
ciently spread from mosquito to human and back
through a domestic cycle that is easily described on a
superficial level; however, numerous studies have sug-
gested that our accounting of the factors involved in
hyperendemic, community, and inter-annual transmis-
sion, among others, remains poorly characterized. It is
widely agreed that enhancing our understanding of these
variable transmission determinants is vital to controlling
outbreaks [3-6]. However, characterization of these fac-
tors and their relative importance on transmission has
been complicated by the lack of a suitable laboratory
model for DENV transmission.
Immunologically intact mouse models have been
shown to be resistant to DENV infections, due to the
ability of their innate immune responses to quickly and
efficiently clear the virus, though success has been seen
with mouse-adapted viruses and/or artificial infection
routes such as intracranial and intraperitoneal injec-
tion [7-13]. The innate immune response certainly en-
gages DENV extracellularly, but once DENV infiltrates
a cell via receptor-mediated endocytosis, (retinol indu-
cible gene-1) RIG-I is stimulated by the presence of
double stranded viral RNA (vRNA). Additionally, mel-
anoma differentiation-associated protein (MDA5) andFigure 1 Type I interferon production signals through IRF3 and IRF7.
cytoplasm and double stranded RNA is recognized in the endosome by TL
transcription of IFN-β, which positively feeds back via STAT1/STAT2/IRF9 toendosomal Toll-like receptor (TLR) -3 recognize
double stranded vRNA intermediates generated during
viral replication. These pathways signal through the
interferon regulatory factors (IRF) 3 and 7, which initi-
ate a cascade of signals resulting in the transcription of
type I interferon (IFN-α and -β) [10]. Figure 1 demon-
strates the importance of IRF3 and IRF7 in the type I
IFN pathway. Briefly, through the activation of these
pathways, (nuclear factor kappa-light-chain-enhancer
of activated B cells) NFκB and IRF3 localize to the nu-
cleus to promote transcription of IFN-β. IFN-β binds
the type I IFN receptor (IFNAR), which leads to the
localization of the (signal transducers and activators of
transcription) STAT1/STAT2/IRF9 complex to the nu-
cleus where IRF7 transcription is promoted. Up-regulated
production of IRF7 leads to increased localization of IRF7
dimers to the nucleus where the production of IFN-α is
promoted. IFN-α and -β are responsible for the establish-
ment and maintenance of the anti-viral state in the
immune response [8-10,14,15].
In vitro studies have shown either that DENV inhibits
type I IFN production or that lack of type I IFN re-
sponse renders mice susceptible, indicating that this
mechanism of immune response subversion is critical
for DENV fitness and thus affects transmission [16-18].
Further, others have shown that downstream protein ex-
pression induced by type I IFN and the (Janus kinase)
JAK/STAT pathway play important roles in DENV in-
hibition [17-21]. Much attention has been given to this
JAK/STAT pathway and it has been suggested that
DENV viral mediated subversion of the type I IFNDouble stranded RNA is recognized by RIG-I and MDA5 in the
R3. The resulting signal cascades all utilize IRF 3 and 7 to first promote
promote transcription of IRF7, which promotes transcription of IFN-α.
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ated [20,22].
Recently, there has been progress towards DENV ver-
tebrate infection models based on these findings with
successful studies involving several knockout mice, par-
ticularly the AG129 model deficient in type I and II
interferon receptors and a more recent C57BL/6 mouse
deficient in type I IFN receptors [18,23-29]. These ani-
mals have most often been used to model DENV disease
and pathogenesis, especially the severe forms of disease
[29-34]. Humanized mice have also shown great promise
for investigating DENV pathogenesis as well as transmis-
sion [34,35]. This is the exception, however, as the use of
many of these animal models for DENV transmission
experiments has yet to be explored.
Accordingly, we assessed the permissiveness of a strain
of C57BL/6 mouse lacking IRF3 and IRF7 (IRF3/7 −/− −/−)
with respect to the transmission of non-mouse adapted
DENV [18,36-38]. Specifically, we investigated the
possibility of non-mouse adapted DENV transmission
to this mouse strain by needle inoculation or via infec-
tious mosquito bite. Subsequently, we determined the
potential for transmission back to mosquitoes from a
viremic animal. Others have established the crucial
role of type I IFN in early clearance of DENV, though
none have sought to explore infection establishment
[39]. In addition, some studies have indicated both
types I and II IFN are necessary for disease progression
[17,39-41]. Herein, we also investigated critical innate
immune markers of progression, comparing infection
establishment and kinetic differences from needle in-
oculation to that of Aedes aegypti mosquito transmis-
sion, as mosquito saliva and salivary gland proteins are




Mice (n = 2) used to detect the replicative strand of
DENV vRNA had equivalent levels of viremia to the
mice used in the analysis, but because they were
sacrificed prior to their probable peak viremia day (48
hours post-infection), they were not included in theFigure 2 Gel showing replicative strand amplification at 48 hours pos
bp), Positive control- Freeze thawed DENV-2 1232 infected Vero cell culture
1 and 2: Samples from inoculation site and draining lymph node of mice inanalyses here (Figure 2). Subsequent transmission of virus
via subcutaneous needle inoculation to IRF3/7 −/− −/−
mice was 100% successful (5/5 positive for DENV).
Viremia levels were centered on the day of peak viremia
(P0, Figure 3). In contrast, none of the DENV-2 inocu-
lated wild type C57BL/6 mice (n = 5) developed detect-
able viremia at any time point (data not shown).
Mosquito versus needle transmission
To detect whether the responses to DENV transmission
are different when IRF3/7 −/− −/− mice were exposed via
infected mosquitoes, we exposed mice to mosquitoes
that were previously orally challenged and later con-
firmed to have a disseminated DENV infection over two
experiments (n = 7, n = 3). Of the ten mice exposed to
infectious mosquitoes, all (10/10) developed viremia.
Viremia levels in mosquito-exposed mice were statisti-
cally higher than those of the needle inoculated mice at
all time points except peak viremia day, P0, and lasted
one day longer (Figure 4). Viremia peaked one day later
post-exposure in mosquito-exposed mice.
Because IFN-γ is a major difference between this and
other currently used immune-deficient mouse models,
we looked at the IFN-γ response to determine if it would
be important in needle versus mosquito exposures. IFN-γ
production rose noticeably in both the mosquito-exposed
and needle-inoculated groups on P1 (Figure 5A). While
the IFN-γ was measurable in the mosquito exposed
mice one day earlier relative to peak day, the needle
inoculated mice had significantly higher IFN-γ levels on
P0 and P1. Additionally, the peak in IFN-γ in mosquito-
exposed mice appears to be delayed to two days post
peak viremia. In both groups, viremia was not detected
following the peak of IFN-γ. Between the needle inocu-
lated and mosquito-exposed mice, there was no signifi-
cant difference in either the IL-4 or the TNF-α response
(Figure 5B-C). In addition, in all groups, IL-1β was
below the limit of detection.
Kinetics of transmission and number of inoculating
mosquitoes
We tested the hypothesis that the number of mosquitoes
may affect transmission kinetics of mosquito-inoculatedt inoculation with DENV-2 1232. Left to Right: Ladder position (~900
; Negative control- Uninfected, age matched Vero cell culture; Samples
oculated with DENV-2 1232, respectively.
Figure 3 Mean viremia and IFN-gamma levels of DENV-2 1232
needle inoculated mice. Mean viremia and IFN-γ levels (+/− SEM)
are centered around viremia peak day (peak = P0). IFN-γ levels
peaked the day following peak viremia.
Figure 5 Cytokine responses in needle-inoculated vs. mosquito-
inoculated infections. A) IFN-γ. The IFN-γ response (+/− SEM) was
significantly higher in the needle inoculated group on days P0 and
P1, as indicated by *. B) TNF-α. Means of serum TNF-α (+/− SEM)
were not significantly different between mosquito and needle
inoculated mice. C) IL-4. Means of serum IL-4 (+/−SEM) were not
significantly different between mosquito and needle inoculated
mice.
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on P0 were not dependent on the number of infectious
mosquitoes to which the mice were exposed (p > 0.05).
The onset of viremia, however, was negatively associated
with the number of infectious mosquitoes transmitting
virus (regression slope = −.012, p < 0.05, Table 1), mean-
ing that more mosquitoes translated into earlier onset of
viremia. The average peak viremia was 7.14 × 102 PFU/
mL (min. 3.0 × 101 PFU/mL, max. 2.15 × 103 PFU/mL).
These results are summarized in Table 1.
Recapitulation of transmission cycle
Three additional mice were exposed to DENV-2 via nee-
dle inoculation in a separate experiment. Naïve mosqui-
toes then fed on these mice during the resulting viremicFigure 4 DENV-2 1232 viremia levels of mosquito vs. needle
inoculated mice. Mean viremia (+/− SEM) in mosquito-inoculated
mice was detectable for one day more than needle inoculated mice
(5 days vs. 4 days, respectively). Viremia levels between the two
treatment groups were statistically different (as indicated by *) at all
times points except peak viremia day, P0.period. Engorged mosquitoes were separated and held
for 16 days post exposure, before being allowed to re-
feed on naïve mice. Immediately afterwards, these mos-
quitoes were tested for DENV titers in the body and
legs. Two out of three mice supported acquisition to
mosquitoes. The mean body and leg titers (PFU/mL) ofTable 1 Summary of transmission from mosquito to IRF3/











P-3 P-2 P-1 P0
1 6 2 0 1.99 1.94E2 1.060E3
2 5 2 0 1.5e1 5.98E1 6.86E2
3 1 3 0 0 4.12 3.0E1
4 2 3 0 0 6.57E1 3.15E2
5 9 2 0 3.3 2.58E1 2.78E2
6 5 2 0 9.82 1.58E2 2.150E3
7 11 2 n/a 0 3.48 1.36E2*
*Indicates peak day for mouse 7 based on our obtained data, but no data was
available for 4 dpi for this mouse. The regression equation used for predicting
day of viremia onset based on the number of infectious mosquitoes feeding
is: Day of viremia onset = 2.88 – 0.012x(# infectious mosquitoes).
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for body and leg (range), respectively: 4.78 × 104 (9.1 × 103-
1.15 × 105) and 2.23 × 103 (1.1 × 101-7 × 103). One or more
of the mosquitoes (n = 3) that acquired DENV from mouse
#1 successfully transmitted virus to a naïve mouse, while
the attempts with the one infectious mosquito from mouse
#2 failed. The viremia curve resulting from that exposure is
given in Figure 6.
Conclusion
We confirmed that the IRF3/7 −/− −/− mouse is a suscep-
tible vertebrate model for DENV infection and transmis-
sion. It has the ability to support non-mouse adapted
DENV strains of serotype 2. Though viral loads did not
approach those seen in human DENV cases, we con-
firmed that the virus was actively replicating, and there-
fore the observed viremia and transmission events were
not due to the initial inoculum acting as a contaminant.
Our finding that DENV was no longer detectable fol-
lowing the peak of IFN-γ in these mice reaffirms the role
of the IFN-γ response in the clearance of DENV infec-
tion [46,47]. This response mirrors the correlation be-
tween IFN-γ response and viremia cessation observed in
children with DENV [46,48]. The association between
IFN-γ response and viremia supports the use of trans-
mission models with intact IFN- γ responses and sug-
gests the potential to use this IRF3/7 −/− −/− mouse for
further inferential efforts to characterize the mechanism
of DENV transmission to humans.
Some differences were noted in the IFN-γ response in
mosquito exposed versus needle-inoculated mice, but
the significance of these differences warrants further
study. Studies have shown that interferon-γ-inducible
protein 10 (IP-10/CXCL10) is an important chemokine
in DENV infection, as DENV resistance has been corre-
lated to increased levels of IP-10 [17,49,50]. More specif-
ically, others have shown that DENV interacts with cell
surface heparan sulfate and that IP-10 directly inhibitsFigure 6 Recapitulation of the DENV transmission cycles. On day 3 po
resulting in three disseminated infections from naïve mosquito exposure.
in the table (II). A naïve mouse was then exposed to these mosquitoes 16
shown (III).this interaction and subsequent infection of new cells
[51]. This would suggest that delaying the peak of IFN-γ,
and thus IP-10, would widen the window for successful
replication and infection of new cells. The mechanistic
origin of these differences, whether based in mosquito
saliva or some intrinsic vertebrate or viral characteristic,
requires investigation, but underscores the further im-
portance of a transmission model with an intact IFN-γ
response. An important limitation of this particular re-
sult is the measurement of systemic cytokine levels. It is
likely that a more significant alteration of the vertebrate
immune response would be seen at the bite site (due to
mosquito salivary secretions) and not necessarily system-
ically. Therefore, it is important to continue to investi-
gate the potential role of mosquito saliva in infection
kinetics in this transmission model.
The finding that viremia was higher in mosquito-
inoculated mice compared to needle inoculated mice is
unsurprising, given that others have shown similar re-
sults with other mosquito borne viruses, such as West
Nile [42]. Further, others have shown that the course of
dengue infection can be affected if delivered by infec-
tious mosquito bite [35]. It is important to note, how-
ever, that mosquitoes in Cox et al. were intrathoracically
inoculated with virus, while our mosquitoes were orally
challenged, representing a more natural course of virus
replication within and subsequent transmission from the
mosquito [35]. While caution should be used when com-
paring the responses of humanized mice to those of
non-humanized mice, our results also indicate an en-
hancement effect of mosquito bite on DENV infection,
demonstrating successful DENV transmission with a sin-
gle infectious mosquito (Table 1).
A significant finding of this study was that this IRF3/
7 −/− −/− mouse strain was able to be both infected by and
transmit virus to mosquitoes, thus providing means to
replicate the natural transmission cycle of DENV. Com-
pletion of the transmission cycle was only successful in 1st infection (dpi), a viremic mouse was fed on by naïve mosquitoes (I),
The resulting body and leg titers from these mosquitoes are shown
dpi and the resulting viremia from that successful transmission is
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have disseminated infections. Since transmission was
achieved in 100% of the other trials (including one other
with only 1 infectious mosquito), it may be that the
probability of transmission when only one infectious
mosquito is feeding is less than 1. Indeed, this is consist-
ent with another study that found consistent results
(vRNA levels, clinical signs) only with greater than 4
mosquitoes [35]. The ability of low levels of viremia
seen in these infected mice to support transmission to
mosquitoes and then subsequent transmission to other
naïve mice confirms the presence of actively replicating,
viable virus. The acquisition of infection by mosquitoes
at these viremia levels suggests important ramifications
for the role of low titer human infections (such as might
occur in inapparent infections or transitional viremic
periods) in overall transmission intensity. Endy, et al. es-
timated that over 60% of DENV infections in a school
cohort were inapparent, and the results from this study
point to the need for investigation into the implications
for low viremic transmission [52,53].
As there is currently no approved vaccine for DENV,
public health monitoring and a greater understanding of
transmission dynamics leading to outbreak events are
critical for DENV prevention. The ability to achieve suc-
cessful infection establishment using natural levels of
viral inoculum from non-mouse adapted DENV strains
is an important step towards studying transmission of
DENV [54]. Further, the recapitulation of the transmis-
sion cycle in this mouse could provide a tool with which
to study the transmission dynamics and kinetics at the
mosquito bite site. The further characterization of
DENV using this model will expand our knowledge of
key entomological, virological and immunological com-
ponents to infection establishment and transmission
events.
Methods
All experiments met the approval and conditions of the
LSU Institutional Animal Care and Use Committee
(protocol # 09–077). LSU IACUC procedures and pol-
icies adhere to and comply with the guidelines stated in
the NIH Guide for the Care and Use of Laboratory Ani-
mals. Mice were maintained by laboratory staff and the
Department of Laboratory Animal Medicine (DLAM) of
the LSU School of Veterinary Medicine.
Mice
Mice were the generous gift of Dr. M. Diamond
(Washington University, St. Louis, MO) with permission
from Dr. T. Taniguchi (University of Tokyo, Tokyo, Japan).
IRF3/7 −/− −/− (double knockout) mice are a strain of
C57BL/6 mice that lack functional IRF 3 and 7, and thus
have a stunted type I IFN response. The type II IFNresponse and all other immune responses are intact,
though diminished [36]. Control mice, wild type C57BL/6
mice, were also included and were obtained from the LSU
DLAM.
Mosquitoes
Aedes aegypti (Rockefeller strain) mosquitoes used in
this study come from a long-standing colony maintained
at the LSU School of Veterinary Medicine. Mosquitoes
are reared in constant environmental conditions and
density. Mosquitoes have access to sucrose-soaked cot-
ton ad libitum until 24 hours prior to experiments.
Virus
Strain 1232 of DENV serotype 2 (DENV-2 1232) virus
was used in these experiments. This strain was originally
isolated from a patient in Indonesia in 1978 (personal
communication, R. Tesh). Virus was propagated in the
C6/36 cell line (Aedes albopictus origin) prior to inocu-
lation into mice to avoid adaptation to mammalian cells.
Before inoculation, virus was titered via plaque assay on
Vero cells and experimental titers from cell supernatant
were confirmed at 106 PFU/mL by qRT-PCR as in [55].
Thus, viral titers are expressed as PFU-equivalents/mL,
symbolized as PFU*/mL. The resultant virus stock of-
fered to mosquitoes via membrane feeder was passaged
in Vero cells, in this case to avoid adaptation to insect
cells.
Virus inoculation and serum collection
Mice (n = 5) were temporarily anesthetized with
isoflurane and injected subcutaneously with 100 μl of
supernatant from the virus inoculated cell culture. Thus,
the total inoculum administered was 105 PFU/mouse of
virus. We chose to needle-inoculate mice on the high
end of the estimate from Styer 2007 et al. and Cox 2012
et al., so that a potential enhancement by mosquito de-
livery would not be attributable to a reduced inoculum
in the needle group [35,54]. Thus differences are a con-
servative estimate since mosquitoes may inoculate less
than 105 PFU/mL.
Mice were then bled each day for five days via sub-
mandibular bleeding technique [56]. Blood was allowed
to clot for thirty minutes at room temperature and then
centrifuged at 6000 rcf for four minutes. Clarified serum
was collected and placed into a clean microcentrifuge
tube for analysis.
Viral detection
vRNA was extracted using the MagMax-96 Total Nu-
cleic Acid isolation kit (Ambion/Life Technologies,
Carlsbad, CA) or QIamp Viral RNA Mini Kit (Qiagen,
Valencia, CA). Serum samples were brought to volume
where necessary with BA-1 diluent and kits were run
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was done using the One-Step TaqMan qRT-PCR assay
(Life Technologies, Carlsbad, CA) as noted above [55].
Verification of viral replication in IRF3/7 −/− −/− mice
To verify that the mouse model supported active viral
replication and that the viremia detected was not simply
residual inoculum, we developed a complement strand
assay to detect only actively replicating virus. From two
mice inoculated with DENV in the same cohort as men-
tioned above, tissue surrounding the inoculation site and
draining lymph nodes were harvested at 48 hours post-
inoculation. The primers used amplified the region be-
tween nucleotides 1503–2418, covering the envelope
protein (1503–2399) and nonstructural protein NS1
(2400–2418): FWD 5′ - GTG CTG CTG CAG ATG
GAA GAC AAA - 3′; REV 5′ - TCA CAA CGC AAC
CAC TAT CAG CCT - 3′. The reference nucleotide se-
quence used to generate the primers and from which
the protein coding positions are taken is “DENV 2 iso-
late DENV-2/CO/BID-V3375/2007, complete genome”
(GenBank: GQ868558.1). Also included were a positive
control of freeze thawed, DENV-2 1232 infected Vero
cell culture supernatant, and a negative control of unin-
fected, age matched Vero supernatant.
Reverse transcriptase (RT)-PCR amplification was car-
ried out using the SuperScript™ III One-Step RT-PCR
System with Platinum® Taq DNA Polymerase (Life Tech-
nologies, Carlsbad, CA) kit on the DNAEngine Peltier
Thermal Cycler (BioRad) with the following protocol.
RT Step (1 cycle): 55°C for 30 minutes, 4°C hold
(indefinite), 94°C for 2 minutes. At the beginning of
the RT step, only the forward primer is included in
order to target only the negative sense RNA strand
generated during DENV replication. During the 4°C
hold, the tubes were removed and a primer mix
containing both the forward and reverse primers is
added. Tubes were replaced and the run continued.
Amplification (40 cycles): 94°C for 15 seconds, 60°C
for 30 seconds, 72°C for 1 minute. Final extension and
Cool Down (1 cycle): 68°C for 5 minutes, 4°C hold.
Samples were then run on a 1% agarose gel and bands
visualized (Figure 2).
Mosquito exposure and transmission to IRF 3/7 −/− −/−
mice
Mosquito inoculated infections occurred in two experi-
mental runs (n1 = 7, n2 = 3, npooled = 10). The results
from these ten mice were pooled as the “mosquito
infected” cohort at LSU School of Veterinary Medicine,
where environmental conditions are held steady. Mos-
quitoes are colony raised, experience consistent rearing
conditions, and do not show the phenotypic plasticity
seen in field caught mosquito populations.Mosquitoes were offered an infectious blood meal
containing DENV 3–5 days post emergence with an in-
fectious titer of 106 PFU/mL. The blood meal consisted
of bovine blood in Alsever’s anticoagulant (Hemostat,
Dixon, CA) mixed 2:1 with a virus solution in a total
volume of approximately 3 mL per carton of mosqui-
toes, heated to 37°C and kept warm via the Hemotek de-
vice (Discovery Workshops, Arrington, Lancashire, UK).
Mosquitoes were allowed to feed for 45 minutes before
the blood meal was removed. Each carton consisted of
approximately 100 mosquitoes and seven cartons were
fed for this study. Engorged females were separated and
placed in new cartons and kept at constant environmen-
tal conditions (16:8 hours light:dark, 28°C, 70-80% hu-
midity). Approximately 50% of mosquitoes were females,
and nearly all fed to repletion before being returned to
the aforementioned environmental conditions for nine
days of extrinsic incubation. Subsequently, seven mice
were anesthetized and placed on top of a carton
containing approximately fifty DENV-exposed mosqui-
toes (1 mouse per carton). After twenty minutes,
engorged mosquitoes were separated based on the pres-
ence of visible blood in the abdomen. Immediately after
feeding on the mice, mosquitoes were frozen, their legs
separated from their abdomens, and tested for virus.
Testing was done via qRT-PCR on the Roche
LightCycler 480 (Roche Diagnostics Corp., Indianapolis,
IN) as previously described [55].
Transmission from viremic mice to mosquitoes
Three mice were inoculated with 105 PFU/mouse of
DENV-2 via needle inoculation as previously described.
Starting at 48 hours post inoculation, and each day
thereafter, mice were anesthetized and placed on top of
cartons (1 mouse per carton) containing naïve mosqui-
toes that had emerged three to four days prior to the be-
ginning of the experiment. Mosquitoes were allowed to
feed for approximately twenty minutes and then the
mice were removed. Engorged females were separated
and placed in clean cartons and kept at constant envir-
onmental conditions as described above. Whole mos-
quito bodies were tested for the presence of virus five
days post exposure to determine infection status.
Cytokine measurement and statistical analysis
IFN-γ, (tumor necrosis factor) TNF-α, (interleukin) IL-4
and IL-1β were measured using the Millipore Milliplex
MAP Mouse Cytokine/Chemokine kit as per manufac-
turer’s instructions (Millipore, Billerica, MA).
Viremia and cytokine levels were statistically analyzed
using analysis of variance (ANOVA) on a daily basis.
Days of detectable viremia were re-centered around the
peak viremia day: three days before peak day (P-3), two
days before peak day (P-2), the day before (P-1), peak
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days after peak (P2). In mosquito inoculated mice, day
of viremia onset and peak viremia level relative to the
number of mosquitoes was analyzed using simple linear
regression. All analyses were performed in SAS 9.13
(PROC MIXED, PROC REG, Carey, NC). Significance is
reported at the α = 0.05 level.
Recapitulation of the transmission cycle
Three mice were inoculated with 105 PFU/mouse of
DENV, serum was collected for virus detection daily,
and mosquitoes were allowed to feed as described above.
Mosquitoes were then held at constant environmental
conditions as described above and at sixteen days post
exposure, the three cohorts of mosquitoes exposed to
the highest viral titers (determined upon testing of
mouse serum) were allowed to re-feed upon naïve mice.
Immediately after re-feeding, mosquitoes were frozen,
legs removed from bodies and tested for infection and
dissemination status as in [55]. These mice were subse-
quently bled daily and serum was collected and tested
for DENV presence and titer.
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